Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Gross Margin (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Gross Margin data on record, last reported at 25.75% in Q4 2025.

  • For Q4 2025, Gross Margin fell 853.0% year-over-year to 25.75%; the TTM value through Dec 2025 reached 18.3%, down 2349.0%, while the annual FY2025 figure was 18.3%, 2349.0% down from the prior year.
  • Gross Margin reached 25.75% in Q4 2025 per MRVI's latest filing, up from 13.58% in the prior quarter.
  • Across five years, Gross Margin topped out at 84.55% in Q2 2022 and bottomed at 13.58% in Q3 2025.
  • Average Gross Margin over 5 years is 54.06%, with a median of 49.67% recorded in 2023.
  • Peak YoY movement for Gross Margin: soared 2797bps in 2021, then crashed -4735bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 82.21% in 2021, then dropped by -10bps to 73.99% in 2022, then decreased by -29bps to 52.65% in 2023, then plummeted by -35bps to 34.28% in 2024, then decreased by -25bps to 25.75% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 25.75% in Q4 2025, 13.58% in Q3 2025, and 16.39% in Q2 2025.